Open Collections

UBC Faculty Research and Publications

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5 Olson, Robert; Liu, Mitchell; Bergman, Alanah; Lam, Sonya; Hsu, Fred; Mou, Benjamin; Berrang, Tanya; Mestrovic, Ante; Chng, Nick; Hyde, Derek; et al.

Abstract

Background: Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1–3 or 1–5 metastases in number. Stereotactic ablative radiotherapy (SABR) is an emerging radiotherapy technique to treat oligometastases that require further prospective population-based toxicity estimates. Methods: This is a non-randomized phase II trial where all participants will receive experimental SABR treatment to all sites of newly diagnosed or progressing oligometastatic disease. We will accrue 200 patients to assess toxicity associated with this experimental treatment. The study was powered to give a 95% confidence on the risk of late grade 4 toxicity, anticipating a < 5% rate of grade 4 toxicity. Discussion: SABR treatment of oligometastases is occurring off-trial at a high rate, without sufficient evidence of its efficacy or toxicity. This trial will provide necessary toxicity data in a population-based cohort, using standardized doses and organ at risk constraints, while we await data on efficacy from randomized phase III trials. Trial Registration Registered through clinicaltrials.gov NCT02933242 on October 14, 2016 prospectively before patient accrual.

Item Metadata

Title
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Creator
Olson, Robert; Liu, Mitchell; Bergman, Alanah; Lam, Sonya; Hsu, Fred; Mou, Benjamin; Berrang, Tanya; Mestrovic, Ante; Chng, Nick; Hyde, Derek; Matthews, Quinn; Lund, Chad; Glick, Daniel; Pai, Howard; Basran, Parminder; Carolan, Hannah; Valev, Boris; Lefresene, Shilo; Tyldesley, Scott; Schellenberg, Devin
Publisher
BioMed Central
Date Issued
2018-10-04
Description
Background: Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1–3 or 1–5 metastases in number. Stereotactic ablative radiotherapy (SABR) is an emerging radiotherapy technique to treat oligometastases that require further prospective population-based toxicity estimates. Methods: This is a non-randomized phase II trial where all participants will receive experimental SABR treatment to all sites of newly diagnosed or progressing oligometastatic disease. We will accrue 200 patients to assess toxicity associated with this experimental treatment. The study was powered to give a 95% confidence on the risk of late grade 4 toxicity, anticipating a < 5% rate of grade 4 toxicity. Discussion: SABR treatment of oligometastases is occurring off-trial at a high rate, without sufficient evidence of its efficacy or toxicity. This trial will provide necessary toxicity data in a population-based cohort, using standardized doses and organ at risk constraints, while we await data on efficacy from randomized phase III trials. Trial Registration Registered through clinicaltrials.gov NCT02933242 on October 14, 2016 prospectively before patient accrual.
Subject
Stereotactic ablative radiotherapy; Oligometastases; Radiotherapy
Genre
Article
Type
Text
Language
eng
Date Available
2018-10-23
Provider
Vancouver : University of British Columbia Library
Rights
Attribution 4.0 International (CC BY 4.0)
DOI
10.14288/1.0372978
URI
http://hdl.handle.net/2429/67678
Affiliation
Other UBC; Non UBC
Citation
BMC Cancer. 2018 Oct 04;18(1):954
Publisher DOI
10.1186/s12885-018-4859-7
Peer Review Status
Reviewed
Scholarly Level
Faculty
Copyright Holder
The Author(s).
Rights URI
http://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution 4.0 International (CC BY 4.0)